Publications by authors named "Alison Meagher"

Claim this Profile
S
Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience.
Mark G Faber, Chong Wang, Sruthi Kommi Reddy, Alison Meagher, Amy Early

Lung Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.
Zachary Schlei, Wei Tan, Mark G Faber, Hongbin Chen, Alison Meagher

Clin Lung Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients.
Samjot Singh Dhillon, Adrienne Groman, Alison Meagher, Todd Demmy, Graham W Warren

J Cancer Sci Ther· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib: a breakthrough for targeted therapies in lung cancer.
Jennifer Kwon, Alison Meagher

J Adv Pract Oncol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analyses of tigecycline tolerability in healthy subjects.
Julie Passarell, Elizabeth Ludwig, Kathryn Liolios, Alison K Meagher, Thaddeus H Grasela

Diagn Microbiol Infect Dis· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.
Paul G Ambrose, Alison K Meagher, Julie A Passarell, Scott A Van Wart, Brenda B Cirincione

Diagn Microbiol Infect Dis· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
Paul G Ambrose, Alison K Meagher, Julie A Passarell, Scott A Van Wart, Brenda B Cirincione

Diagn Microbiol Infect Dis· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetic and pharmacodynamic profile of tigecycline.
Alison K Meagher, Paul G Ambrose, Thaddeus H Grasela, Evelyn J Ellis-Grosse

Clin Infect Dis· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
Alison K Meagher, Paul G Ambrose, Thaddeus H Grasela, Evelyn J Ellis-Grosse

Diagn Microbiol Infect Dis· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.
Alison K Meagher, Alan Forrest, Axel Dalhoff, Heino Stass, Jerome J Schentag

Antimicrob Agents Chemother· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.
Craig R Rayner, Alan Forrest, Alison K Meagher, Mary C Birmingham, Jerome J Schentag

Clin Pharmacokinet· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.
Jerome J Schentag, Alison K Meagher, Alan Forrest

Ann Pharmacother· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.
Jerome J Schentag, Alison K Meagher, Alan Forrest

Ann Pharmacother· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.
Alison K Meagher, Alan Forrest, Craig R Rayner, Mary C Birmingham, Jerome J Schentag

Antimicrob Agents Chemother· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.
Mary C Birmingham, Craig R Rayner, Alison K Meagher, Susan M Flavin, Donald H Batts

Clin Infect Dis· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis.
Marianne Ferrin, Jonathan B Zuckerman, Alison Meagher, Emily A Blumberg

Pediatr Pulmonol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis